熱門資訊> 正文
Eliem Therapeutics GAAP每股收益为-0.13美元，击败0.02美元
2025-03-26 04:38
- Eliem Therapeutics press release (NASDAQ:CLYM): Q4 GAAP EPS of -$0.13 beats by $0.02.
- Cash, cash equivalents and marketable securities were $212.5 million as of December 31, 2024, as compared to $106.8 million as of December 31, 2023. Cash, cash equivalents and marketable securities are expected to fund operations through 2027.
More on Eliem Therapeutics
- Seeking Alpha’s Quant Rating on Eliem Therapeutics
- Historical earnings data for Eliem Therapeutics
- Financial information for Eliem Therapeutics
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
